Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Cytosorbents (CTSO) Other financing activities (2017 - 2026)

Cytosorbents filings provide 4 years of Other financing activities readings, the most recent being $886000.0 for Q4 2025.

On a quarterly basis, Other financing activities changed N/A to $886000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a N/A change, with the full-year FY2025 number at $2.8 million, down 26.46% from a year prior.
Other financing activities hit $886000.0 in Q4 2025 for Cytosorbents, up from $488000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $886000.0 in Q4 2025 to a low of $488000.0 in Q3 2025.